Roflumilast for asthma: Efficacy findings in mechanism of action studies

Pulmonary Pharmacology and Therapeutics

Volumn 35, Issue , 2015, Pages S4-S10

  Bardin, P ^a   Kanniess, F ^b   Gauvreau, G ^c   Bredenbroker D ^d   Rabe, K F ^e,f  

^a MONASH MEDICAL CENTRE   (Australia)

^b Practice for Allergy and Family Medicine   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

^d Takeda Pharmaceuticals International GmbH   (Switzerland)

^e Lung Clinic Großhansdorf   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

Author keywords

Allergen; Asthma; Eosinophil; FEV1; Roflumilast

Indexed keywords

ALLERGEN; BIOLOGICAL MARKER; LEUKOTRIENE E4; NITRIC OXIDE; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA; AMINOPYRIDINE DERIVATIVE; BENZAMIDE DERIVATIVE; CYCLOPROPANE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR;

ADULT; AGED; ALLERGIC REACTION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; BRONCHOCONSTRICTION; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; EOSINOPHIL COUNT; EUROPE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPHIL COUNT; NORTH AMERICA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOUTH AMERICA; SPUTUM CULTURE; ADOLESCENT; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOLOGY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMINOPYRIDINES; ASTHMA; BENZAMIDES; CROSS-OVER STUDIES; CYCLOPROPANES; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; HUMANS; MIDDLE AGED; PHOSPHODIESTERASE 4 INHIBITORS; SPUTUM; YOUNG ADULT;

EID: 84941670924     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.08.006     Document Type: Article

References (22)

1. Global strategy for asthma management and prevention. Global initiative for asthma (GINA) 2014, Available from:. http://www.ginasthma.org/.
2. Pandya D., Puttanna A., Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir. Med. J. 2014, 8:59-65.
3. Zheng J., Yang J., Zhou X., et al. Roflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group study. Chest 2014, 145:44-52.
4. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L., et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009, 374:695-703.
5. Rennard S.I., Calverley P.M., Goehring U.M., et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir. Res. 2011, 12:18.
6. Bousquet J., Chanez P., Lacoste J.Y., et al. Eosinophilic inflammation in asthma. N. Engl. J. Med. 1990, 323:1033-1039.
7. Kanniess F., Beier J., Beeh K.M., et al. Effects of roflumilast on exhaled NO, airway hyper responsiveness, and inflammatory markers in patients with asthma. Eur. Respir. J. 2006, 28(Suppl. 50):670s.
8. Louw C., Williams Z., Venter L., et al. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyper responsiveness after allergen challenge. Respiration 2007, 74:411-417.
9. van Schalkwyk S.E., Strydom K., Williams Z., et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J. Allergy Clin. Immunol. 2005, 116:292-298.
10. Gauvreau G.M., Boulet L.P., Schmid-Wirlitsch C., et al. Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir. Res. 2011, 12:140.
11. Engelstaetter R., Wingertzahan M., Schmid-Wirlitsch C., et al. Roflumilast, an oral, once-daily phosphodiesterase 4 (PDE4) inhibitor, does not exhibit bronchodilatory activity. Ann. Allergy Asthma Immunol. 2005, 94:169.
12. Hargreave F.E., Boulet L.P., Cartier A., et al. The effect of roflumilast on sputum eosinophils in patients with asthma. Am. Coll. Allergy Asthma Immunol. Congr. 2005, 79:P157.
13. Inman M., Watson R.M., Rerecich T., et al. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am. J. Respir. Crit. Care Med. 2001, 164:569-574.
14. Kidney J.C., Boulet L.P., Hargreave F.E. Evaluation of single-dose inhaled corticosteroid activity with an allergen challenge model. J. Allergy Clin. Immunol. 1997, 100:65-70.
15. Grootendorst D.C., Gauw S.A., Verhoosel R.M., et al. Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007, 62:1081-1087.
16. Keatings V.M., Barnes P.J. Granulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjects. Am. J. Respir. Crit. Care Med. 1997, 155:449-453.
17. Jatakanon A., Uasuf C., Maziak W., et al. Neutrophilic inflammation in severe persistent asthma. Am. J. Respir. Crit. Care Med. 1999, 160:1532-1539.
18. Green R.H., Brightling C.E., Woltmann G., et al. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002, 57:875-879.
19. Fahy J.V., Kim K.W., Liu J., et al. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J. Allergy Clin. Immunol. 1995, 95:843-852.
20. Martin R.J., Cicutto L.C., Smith R.H., et al. Airways inflammation in nocturnal asthma. Am. Rev. Respir. Dis. 1991, 143:351-357.
21. Calverley P.M., Rabe K.F., Goehring U.M., et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009, 374:685-694.
22. Martinez F.J., Calverley P.M., Goehring U.M., et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015, 385:857-866.